Recherche
-
Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active-controlled trial in Guinea and Sierra Leone
(Lancet Global Health. vol. 11, n° 11, pp. e1743-e1752, 2023-11)Article de revueLibre accès -
ChatGPT and beyond with artificial intelligence (AI) in health: Lessons to be learned.
(Joint Bone Spine. vol. 90, n° 5, pp. 105607, 2023-09-01)Article de revue -
Random survival forests with multivariate longitudinal endogenous covariates
(Statistical Methods in Medical Research. vol. 32, n° 12, pp. 2331-2346, 2023-12-01)Article de revueLibre accès -
Acute respiratory distress syndrome after SARS-CoV-2 infection on young adult population: International observational federated study based on electronic health records through the 4CE consortium
(PLoS ONE. vol. 18, n° 1, pp. e0266985, 2023-04-05)Article de revueLibre accès -
Development and external validation of a prediction model for the transition from mild to moderate or severe form of COVID-19
(European Radiology, 2023-07-05)Article de revueLibre accès -
Prediction of long-term humoral response induced by the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola
(NPJ vaccines. vol. 8, n° 1, pp. 174, 2023-11-08)Article de revueLibre accès -
Identification of early gene expression profiles associated with long-lasting antibody responses to the Ebola vaccine Ad26.ZEBOV/MVA-BN-Filo
(Cell Reports. vol. 42, n° 9, pp. 113101, 2023-09-26)Article de revueLibre accès -
Serious Games for Training in Patient Flow Management in Emergency Departments: State of the Art and Perspectives
Communication dans un congrèsLibre accès -
Safety and Immunogenicity of Hpv Vaccination in Immunocompromised Girls: The Primavera Clinical Trial (Nct 01687192)
Communication dans un congrès -
Immunogenicity and vaccine shedding after 1 or 2 doses of rVZVDeltaG-ZEBOV-GP Ebola vaccine (ERVEBO(R)): Results from a phase 2, randomized, placebo-controlled trial in children and adults
(Clinical Infectious Diseases, 2023-11-15)Article de revueLibre accès